What is the appropriate domperidone dosage for a 2‑year‑old child?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 3, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Domperidone Dosing for a 2-Year-Old Child

For a 2-year-old child, domperidone should be dosed at 0.2–0.25 mg/kg per dose, given three times daily before meals, which translates to approximately 0.6–0.75 mg/kg per day total. 1

Weight-Based Dosing Calculation

  • A typical 2-year-old weighs approximately 12–13 kg, so the practical dose would be 2.4–3.25 mg per dose, three times daily (total daily dose of 7.2–9.75 mg/day). 1
  • The dose should be administered before meals to optimize gastric emptying effects. 2

Evidence Supporting This Dosing Regimen

The recommended dosing is derived from older pediatric studies that demonstrated efficacy:

  • A 1979 double-blind trial in infants and children used 0.3 mg/kg three times daily and found domperidone significantly superior to both metoclopramide and placebo for chronic vomiting and regurgitation. 2
  • A 2006 uncontrolled study used 0.2 mg/kg three times daily in infants with reported symptom improvement, though this evidence is of lower quality. 1
  • A 1981 pediatric oncology study identified 0.7 mg/kg per dose as optimal for chemotherapy-induced nausea and vomiting, but this higher dose was for acute severe nausea in older children, not routine use in toddlers. 3

Critical Safety Considerations and Contraindications

Domperidone carries significant cardiac risks and regulatory restrictions that must be acknowledged:

  • The European Medicines Agency (EMA) restricted domperidone use in 2014 to patients ≤60 years, maximum 30 mg/day, and duration ≤7 days due to sudden death risk and QT prolongation. 4
  • A 2019 randomized controlled trial in children 6 months to 12 years with acute gastroenteritis using 0.25 mg/kg three times daily showed no significant benefit over placebo for reducing vomiting or nausea episodes, raising questions about efficacy. 5
  • No deaths or QT prolongation were reported in the 2019 pediatric trial, suggesting short-term low-dose use may have an acceptable safety profile, though the study was terminated early for futility. 5

Practical Dosing Algorithm

For a 2-year-old with gastroesophageal reflux or gastroparesis symptoms:

  1. Calculate weight-based dose: 0.2–0.25 mg/kg per dose
  2. Administer three times daily before meals (approximately every 8 hours)
  3. Maximum daily dose should not exceed 0.75 mg/kg/day or 30 mg/day total (whichever is lower)
  4. Limit treatment duration to 7 days unless compelling clinical need justifies longer use with cardiac monitoring 4

Common Pitfalls to Avoid

  • Do not exceed 0.3 mg/kg per dose in routine practice, as higher doses (0.7 mg/kg) were studied only in acute chemotherapy-induced nausea in older children. 3
  • Avoid prolonged use beyond 7 days without documented cardiac monitoring (baseline and follow-up ECG to assess QTc interval). 4, 6
  • Do not use in children with known cardiac conduction abnormalities, electrolyte disturbances, or concurrent QT-prolonging medications. 6
  • Recognize that domperidone is used "off-label" in most pediatric gastrointestinal conditions, as current regulatory approval is restricted to nausea/vomiting in children >12 years. 7

Pharmacokinetic Considerations

  • Population pharmacokinetic data in preterm neonates showed mean peak plasma concentrations of 25.3 ng/mL and trough of 15.4 ng/mL at 0.75 mg/kg/day, with clearance similar to adults, suggesting the dosing regimen is appropriate across pediatric ages. 8
  • Oral absorption is adequate in young children, with no need for dose adjustment based on age alone within the pediatric population. 8

Alternative Considerations

Given the lack of proven efficacy in the most recent high-quality pediatric trial 5 and significant regulatory restrictions 4, clinicians should carefully weigh the risk-benefit ratio and consider alternative therapies (e.g., dietary modifications, positioning, acid suppression if indicated) before initiating domperidone in a 2-year-old child.

References

Guideline

Pediatric Dosing for Domperidone

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Domperidone as an antiemetic in paediatric oncology.

Cancer chemotherapy and pharmacology, 1981

Research

Cardiac safety and clinical efficacy of high-dose domperidone for long-term treatment of gastroparesis symptoms.

Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2022

Research

Drugs in Focus: Domperidone.

Journal of pediatric gastroenterology and nutrition, 2023

Research

Population pharmacokinetics of domperidone in preterm neonates.

European journal of clinical pharmacology, 2008

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.